{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:33:15Z","timestamp":1792783995789,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Key Project of NSFC for International Cooperation","award":["81420108027"],"award-info":[{"award-number":["81420108027"]}]},{"name":"Key Research and Development Project of Shandong Province","award":["2017CXGC1401"],"award-info":[{"award-number":["2017CXGC1401"]}]},{"name":"Key Research and Development Project of Shandong Province","award":["2019JZZY021011"],"award-info":[{"award-number":["2019JZZY021011"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejmech.2020.113051","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T11:37:52Z","timestamp":1606477072000},"page":"113051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties"],"prefix":"10.1016","volume":"213","author":[{"given":"Xiangyi","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boshi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fisayo A.","family":"Olotu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik","family":"De Clercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud E.S.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Pannecouque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7302-2214","authenticated-orcid":false,"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2020.113051_bib1","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1128\/AAC.00591-12","article-title":"Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors","volume":"56","author":"Asahchop","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2020.113051_bib2","doi-asserted-by":"crossref","first-page":"28961","DOI":"10.1039\/C9RA05869A","article-title":"Discovery of novel 1,4-disubstituted 1,2,3-triazole phenylalanine derivatives as HIV-1 capsid inhibitors","volume":"9","author":"Jiang","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2020.113051_bib3","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36340","article-title":"Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-d] pyrimidine non-nucleoside inhibitors","volume":"7","author":"Yang","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2020.113051_bib4","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ejmech.2018.06.036","article-title":"5-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase","volume":"155","author":"Sun","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113051_bib5","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nsb0495-293","article-title":"High resolution structures of HIV-1 RT from four RT-inhibitor complexes","volume":"2","author":"Ren","year":"1995","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.ejmech.2020.113051_bib6","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1039\/C7OB02828H","article-title":"Discovery of novel diarylpyrimidines as potent HIV-1 NNRTIs by investigating the chemical space of a less explored \"hydrophobic channel","volume":"16","author":"Zhou","year":"2018","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2020.113051_bib7","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","article-title":"The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic","volume":"62","author":"Namasivayam","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113051_bib8","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/nm0703-867","article-title":"Twenty years of therapy for HIV-1 infection","volume":"9","author":"Pomerantz","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2020.113051_bib9","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/med.20241","article-title":"HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design","volume":"33","author":"Zhan","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2020.113051_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/QAI.0b013e3182515730","article-title":"Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment","volume":"60","author":"Lehman","year":"2012","journal-title":"J.\u00a0Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.ejmech.2020.113051_bib11","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJMra1004180","article-title":"Mechanisms of disease development of antiretroviral drug resistance","volume":"365","author":"Wainberg","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.113051_bib12","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ejmech.2015.01.042","article-title":"Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches","volume":"92","author":"Huang","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113051_bib13","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejmech.2018.09.013","article-title":"Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors","volume":"158","author":"Gu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113051_bib14","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/med.21544","article-title":"Challenges and approaches in the discovery of human immunodeficiency virus type-1 non-nucleoside reverse transcriptase inhibitors","volume":"39","author":"Battini","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2020.113051_bib15","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMp1710608","article-title":"HIV drug resistance - an emerging threat to epidemic control","volume":"377","author":"Beyrer","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2020.113051_bib16","first-page":"41","article-title":"Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir","volume":"5","author":"Wainberg","year":"2013","journal-title":"HIV AIDS (Auckl)"},{"key":"10.1016\/j.ejmech.2020.113051_bib17","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.apsb.2019.08.013","article-title":"Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 NNRTIs","volume":"10","author":"Kang","year":"2020","journal-title":"Acta Pharmacol. Sin. B"},{"key":"10.1016\/j.ejmech.2020.113051_bib18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/13543776.2016.1113256","article-title":"Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1","volume":"26","author":"Huang","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2020.113051_bib19","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.cclet.2020.03.028","article-title":"New techniques and strategies in drug discovery","volume":"31","author":"Du","year":"2020","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.113051_bib20","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.apsb.2019.08.009","article-title":"Synthesis and biological evaluation of a series of 2-(((5-akly\/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimidin-4(3H)-ones as potential HIV-1 inhibitors","volume":"10","author":"Wu","year":"2020","journal-title":"Acta Pharmacol. Sin. B"},{"key":"10.1016\/j.ejmech.2020.113051_bib21","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1021\/jm901241e","article-title":"Escape from flatland: increasing saturation as an approach to improving clinical success","volume":"52","author":"Lovering","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113051_bib22","doi-asserted-by":"crossref","first-page":"7737","DOI":"10.1039\/C4CS00477A","article-title":"Pharmaceuticals that contain polycyclic hydrocarbon scaffolds","volume":"44","author":"Stockdale","year":"2015","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2020.113051_bib23","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1039\/C5OB02539G","article-title":"An approach to \"escape from flatland\": chemo-enzymatic synthesis and biological profiling of a library of bridged bicyclic compounds","volume":"14","author":"Birudukota","year":"2016","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2020.113051_bib24","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1021\/acsmedchemlett.9b00409","article-title":"Escaping from flatland: [2+2] photocycloaddition; conformationally constrained sp(3)-rich scaffolds for lead generation","volume":"10","author":"Cox","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.113051_bib25","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1080\/17460441.2019.1653849","article-title":"Fragment-based screening with natural products for novel anti-parasitic disease drug discovery","volume":"14","author":"Liu","year":"2019","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2020.113051_bib26","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1021\/acsmedchemlett.0c00039","article-title":"Escaping from flatland: substituted bridged pyrrolidine fragments with inherent three-dimensional character","volume":"11","author":"Cox","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2020.113051_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2020.07.017","article-title":"Fsp(3): a new parameter for drug-likeness","author":"Wei","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2020.113051_bib28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1021\/ci300445e","article-title":"3D molecular descriptors important for clinical success","volume":"53","author":"Kombo","year":"2013","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2020.113051_bib29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejmech.2016.05.054","article-title":"Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket","volume":"121","author":"Chen","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113051_bib30","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/med.21581","article-title":"Molecular design opportunities presented by solvent-exposed regions of target proteins","volume":"39","author":"Jiang","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2020.113051_bib31","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1021\/acs.jmedchem.8b01729","volume":"62","author":"Huang","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113051_bib32","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nprot.2007.517","article-title":"Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later","volume":"3","author":"Pannecouque","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2020.113051_bib33","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1021\/acs.jmedchem.6b00738","article-title":"Design, synthesis, and evaluation of thiophene[3,2-d]pyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors with significantly improved drug resistance profiles","volume":"59","author":"Kang","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113051_bib34","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1021\/ci4002475","article-title":"MMGBSA as a tool to understand the binding affinities of filamin-peptide interactions","volume":"53","author":"Ylilauri","year":"2013","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2020.113051_bib35","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcms.2014.10.026","article-title":"Gender differences in posed smiles using principal component analysis","volume":"43","author":"Mishima","year":"2015","journal-title":"J\u00a0Cranio Maxill Surg"},{"key":"10.1016\/j.ejmech.2020.113051_bib36","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1021\/jm000942e","article-title":"Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties","volume":"43","author":"Ertl","year":"2000","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113051_bib37","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2174\/1389203719666190527080832","article-title":"Ligand potency, efficiency and drug-likeness: a story of intuition, misinterpretation and serendipity","volume":"20","author":"Polanski","year":"2019","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.ejmech.2020.113051_bib38","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/jps.22242","article-title":"Physicochemical properties of the amorphous drug, cast films, and spray dried powders to predict formulation probability of success for solid dispersions: etravirine","volume":"100","author":"Weuts","year":"2011","journal-title":"J\u00a0Pharm Sci-US"},{"key":"10.1016\/j.ejmech.2020.113051_bib39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0166-0934(93)90054-U","article-title":"Poly a-linked colorimetric microtiter plate Assay for hiv reverse-transcriptase","volume":"44","author":"Suzuki","year":"1993","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.ejmech.2020.113051_bib40","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1016\/j.ejmech.2007.12.015","article-title":"Design and synthesis of 2-(2,6-dibromophenyl)-3-heteroaryl-1, 3-thiazolidin-4-ones as anti-HIV agents","volume":"43","author":"Rawal","year":"2008","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2020.113051_bib41","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1063\/1.464913","article-title":"Perspective on \"Density functional thermochemistry. III. The role of exact exchange\" - becke AD","volume":"98","author":"Raghavachari","year":"1993","journal-title":"J.\u00a0Chem. Phys."},{"key":"10.1016\/j.ejmech.2020.113051_bib42","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/jcc.20290","article-title":"The Amber biomolecular simulation programs","volume":"26","author":"Case","year":"2005","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2020.113051_bib43","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF chimera - a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J.\u00a0Comput. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420310230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523420310230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:30:19Z","timestamp":1759329019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523420310230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":43,"alternative-id":["S0223523420310230"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.113051","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp3 values and favorable drug-like properties","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2020.113051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113051"}}